Newamsterdam Pharma Company N.V. - (NAMS) closed at $19.18 on November 10, 2026, up 0.9% from the previous close, on volume of 2,282,294 shares (30-day average 1,464,631).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 12, 2026 | Diagonal Double Call Spread | 16-Oct-2625 : 30 C|20-Nov-2622.5 : 25 C | 1,160 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Cantor Fitzgerald Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TipRanks (Wed, 11-Nov 7:36 AM ET)
Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Helus Pharma (HELP)
TipRanks (Mon, 9-Nov 11:20 AM ET)
Piper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
TipRanks (Mon, 9-Nov 9:25 AM ET)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 6-Nov 4:01 PM ET)
TipRanks (Fri, 6-Nov 8:58 AM ET)
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
Globe Newswire (Wed, 4-Nov 7:30 AM ET)
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
Globe Newswire (Tue, 3-Nov 8:00 AM ET)
Globe Newswire (Tue, 29-Sep 8:00 AM ET)
Globe Newswire (Mon, 21-Sep 9:00 AM ET)
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Newamsterdam Pharma Company N.V. - trades on the NASDAQ stock market under the symbol NAMS.
As of November 11, 2026, NAMS stock price climbed to $20.44 with 1,069,939 million shares trading.
NAMS has a beta of 1.34, meaning it tends to be more sensitive to market movements. NAMS has a correlation of 0.09 to the broad based SPY ETF.
NAMS has a market cap of $2.45 billion. This is considered a Mid Cap stock.
Last quarter Newamsterdam Pharma Company N.V. - reported $19 million in Revenue and -$.14 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.31.
In the last 3 years, NAMS traded as high as $42.21 and as low as $8.64.
The top ETF exchange traded funds that NAMS belongs to (by Net Assets): CGMM, IBB, VHT, SBIO, ESML.
NAMS has underperformed the market in the last year with a return of -47.5%, while the SPY ETF gained +12.8%. In the last 3 month period, NAMS fell short of the market, returning -26.9%, while SPY returned -1.3%. However, in the most recent 2 weeks NAMS has outperformed the stock market by returning -0.3%, while SPY returned -1.1%.
NAMS support price is $18.43 and resistance is $19.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NAMS shares will trade within this expected range on the day.
